Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (211-220 of 404) with videos related to

Pageof 41
Sort By:
Journal of Hepatology|September 15, 2020
High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, AustraliaHeather Valerio, Maryam Alavi, Matthew Law, et al.
The International Journal on Drug Policy|July 7, 2015
The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS studyEmmanuel Fortier, Maryam Alavi, Michelle Micallef, et al.
AIDS (London, England)|May 5, 2012
Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infectionJason Grebely, Margaret Hellard, Tanya Applegate, et al.
Journal of Hepatology|July 13, 2010
Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosingWendy S C Cheng, Stuart K Roberts, Geoffrey McCaughan, et al.
Antiviral Therapy|April 20, 2012
Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patientsDarrell H G Crawford, Gregory J Dore, William Sievert, et al.
The International Journal on Drug Policy|October 14, 2022
Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage studyHeather Valerio, Anna Conway, Maryam Alavi, et al.
AIDS (London, England)|July 9, 2009
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individualsGail V Matthews, Eric Seaberg, Gregory J Dore, et al.
The Journal of Infectious Diseases|February 24, 2009
Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapyMegan Crane, Ben Oliver, Gail Matthews, et al.
Journal of Virology|January 8, 2010
No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapyMegan Crane, Sunee Sirivichayakul, J Judy Chang, et al.
Journal of Hepatology|December 1, 2019
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysisBehzad Hajarizadeh, Evan B Cunningham, Heather Valerio, et al.
Pageof 41

Showing results (211-220 of 404) with videos related to

Sort By:
Pageof 41
Journal of Hepatology|September 15, 2020
High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, AustraliaHeather Valerio, Maryam Alavi, Matthew Law, et al.
The International Journal on Drug Policy|July 7, 2015
The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS studyEmmanuel Fortier, Maryam Alavi, Michelle Micallef, et al.
AIDS (London, England)|May 5, 2012
Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infectionJason Grebely, Margaret Hellard, Tanya Applegate, et al.
Journal of Hepatology|July 13, 2010
Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosingWendy S C Cheng, Stuart K Roberts, Geoffrey McCaughan, et al.
Antiviral Therapy|April 20, 2012
Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patientsDarrell H G Crawford, Gregory J Dore, William Sievert, et al.
The International Journal on Drug Policy|October 14, 2022
Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage studyHeather Valerio, Anna Conway, Maryam Alavi, et al.
AIDS (London, England)|July 9, 2009
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individualsGail V Matthews, Eric Seaberg, Gregory J Dore, et al.
The Journal of Infectious Diseases|February 24, 2009
Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapyMegan Crane, Ben Oliver, Gail Matthews, et al.
Journal of Virology|January 8, 2010
No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapyMegan Crane, Sunee Sirivichayakul, J Judy Chang, et al.
Journal of Hepatology|December 1, 2019
Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysisBehzad Hajarizadeh, Evan B Cunningham, Heather Valerio, et al.
Pageof 41